Han H et al.microRNA-206 impairs c-Myc-driven cancer in a synthetic lethal manner by directly inhibiting MAP3K13.Oncotarget 7:16409-19 (2016).
Myant K et al.Serine 62-Phosphorylated MYC Associates with Nuclear Lamins and Its Regulation by CIP2A Is Essential for Regenerative Proliferation.Cell Rep 12:1019-31 (2015).
Cianfanelli V et al.AMBRA1 links autophagy to cell proliferation and tumorigenesis by promoting c-Myc dephosphorylation and degradation.Nat Cell Biol 17:20-30 (2015).
Kauko O et al.Label-free quantitative phosphoproteomics with novel pairwise abundance normalization reveals synergistic RAS and CIP2A signaling.Sci Rep 5:13099 (2015).
Ischenko I et al.Analysis of the tumor-initiating and metastatic capacity of PDX1-positive cells from the adult pancreas.Proc Natl Acad Sci U S A 111:3466-71 (2014).
Mannava S et al.PP2A-B56a controls oncogene-induced senescence in normal and tumor human melanocytic cells.Oncogene 31:1484-92 (2012).
Tibbitts DC et al.Studying c-Myc serine 62 phosphorylation in leukemia cells: concern over antibody cross-reactivity.Blood 119:5334-5 (2012).
Tsai WB et al.Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells.Cancer Res 72:2622-33 (2012).
Chung EY et al.CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis.J Clin Invest 122:2257-66 (2012).
Kapeli K & Hurlin PJ Differential Regulation of N-Myc and c-Myc Synthesis, Degradation, and Transcriptional Activity by the Ras/Mitogen-activated Protein Kinase Pathway.J Biol Chem 286:38498-508 (2011).
Junttila MR et al.CIP2A inhibits PP2A in human malignancies.Cell 130:51-62 (2007).